Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Puts Accutane On Import Alert Ahead Of Congressional Hearing On Safety

Executive Summary

FDA is seeking to curb personal importation of Roche's Accutane by mail by placing the acne therapy on its import alert list

You may also be interested in...



Grassley Import Bill Offers R&D Tax Credit To Cooperating Manufacturers

A drug reimportation bill introduced by Sen. Charles Grassley (R-Iowa) April 8 would provide an R&D tax incentive to pharmaceutical manufacturers who do not try to prevent imports

Grassley Import Bill Offers R&D Tax Credit To Cooperating Manufacturers

A drug reimportation bill introduced by Sen. Charles Grassley (R-Iowa) April 8 would provide an R&D tax incentive to pharmaceutical manufacturers who do not try to prevent imports

FDA Import Crackdown Escalates With DoJ Suit Vs. Canadian Pharmacy Site

FDA is escalating its enforcement against drug reimportation through a Department of Justice suit against a Canadian pharmacy operation

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel